Solidly promote the "three drop three improve" and vigorously carry out technical research
Release time:
2020-08-14
Solidly Pushing Forward "Three Decreases and Three Improves" Vigorously Carrying out Technical Research
Group Company 2017 Advanced Enterprise Pharmaceutical Company Jinxi Pharmaceutical Factory
Review 2017 , Jinxi Factory received nearly 100 visits and exchanges, through many surprise inspections and drug sampling inspections by drug supervision, safety supervision, environmental protection, and fire protection departments, the normal supply of various products has been guaranteed under the circumstances of stricter supervision and tight supply. In the case of a significant increase in raw and auxiliary packaging materials and labor costs, the cost of the preparation is saved 625 . The sharp drop in production costs is mainly due to the solid advancement of the "three reductions and three improvements" work and the vigorous development of technical research projects.
2017 , the whole factory completed a total of "three reductions and three improvements" measures 75 , covering energy, materials and labor costs. In terms of electricity consumption, after the implementation of all measures, Jinxi Factory will save electricity 100 degrees per year, accounting for 10% of the annual electricity consumption. The renovation of the blower in the sewage station saves electricity 5 degrees / years; After the renovation of the laboratory refrigeration system, electricity can be saved 70560 degrees every summer. However, the power center and the preparation workshop can save basic electricity charges 7.68 yuan and 5.12 yuan respectively through the overall arrangement of steam, only by reporting 24 hours, the basic cost 1400 yuan can be saved. The negotiated change of the liquid hazardous waste disposal unit can not only realize the exemption of hazardous waste transportation and disposal fees, but also charge part of the solvent transfer fee, which can save the cost of 26 yuan / years based on the annual disposal of liquid waste 73 tons. The decrease in the cost of raw materials used in
formulations is closely related to the increase in solvent recovery and technical research efforts in the raw material workshop. The solution to the problem of insoluble particles in methyl oxime raw materials has realized the continuous production of products. Through the adjustment and transformation of multiple processes, the yield has increased by 13% , and the cost per batch has decreased by 1.4 yuan. Paroxetine hydrochloride and amlodipine aspartate have carried out six technical research at the same time, greatly saving the cost of raw materials.
2017 , although the number of people in Jinxi Factory did not decrease significantly, under the condition that the employment gap reached 20% , it not only ensured the normal supply of its own products, but also digested the 2000 jobs required for the centralized operation of new products and contract manufacturing business, it also solved the problem of serious labor shortage when half of the site QA took maternity leave and the three lines of the raw material workshop were opened at the same time, thanks to the compression and allocation of labor in QA and the workshop.
2017 Annuity West Factory has completed the replacement of the heads of powder injection and raw material workshops at the same time. At present, all the managers in each workshop are relatively young. They are active in thinking, enterprising and innovative. Over the years, the inheritance of Jiangnan Factory has also made the managers at all levels lack the work style of loyalty, unity, truth-seeking and pragmatism, and responsibility, it is believed that they can not only ensure the normal work of the workshop, but also wait for the dispatch of the company's new projects at any time.
2018 We will strengthen safety and environmental protection, strengthen and optimize employment management, do a good job in on-site standardized operation, change staff training methods, and adjust personnel appointment measures. I believe that all employees of Jinxi Factory can work hard under the strong leadership of the company and strive to complete the objectives and tasks of 2018 , adding luster to the 60th anniversary of the group's entrepreneurship and the 20th anniversary of the establishment of the pharmaceutical industry! (according to the speech made by Zheng kunwu, executive deputy director of Jinxi pharmaceutical factory, pharmaceutical company, at the summary commendation meeting of the group company)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page